Pfizer Inc. (PFE)
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
Pfizer appoints James List to lead development of obesity medicines
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, which includes development of cardiovascular and obesity medicines.
Final Trades: Pfizer, Paychex and the JEPI
The Investment Committee debates their Final Trades.
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
Pfizer: It's Time To Play Defensive
Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely to be quite positive for Pfizer, as the optimism around growth stocks is fading. Patent cliff risks exist, but Pfizer's substantial R&D investments and solid fundamentals make it a compelling high-yield investment.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.
3 Ultra-Cheap Dividend Stocks to Buy Right Now
If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years.
1 Stock Down 43% That Looks Too Cheap to Ignore
Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Despite modest 2025 guidance, Pfizer's oncology and anti-obesity drugs present growth potential, countering analysts' low expectations. However, risks remain, which include political challenges and patent expirations.
Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
Pfizer's CEO said he may move manufacturing back to the US in response to Donald Trump's tariffs. Albert Bourla said he was not surprised by Trump's victory in November.
Pfizer Inc. (PFE) TD Cowen 45th Annual Health Care Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) TD Cowen 45th Annual Health Care Conference March 3, 2025 10:30 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again, and welcome to TD Cowen's 45th Annual Healthcare Conference. We are absolutely delighted to have Pfizer with us again this year.
Pfizer could move outside manufacturing to the US, says CEO
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported goods.
